Work

Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds

Year: 2016

Type: article

Abstract: // Anastasiya A. Chumanevich 1 , Anusha Chaparala 1 , Erin E. Witalison 1 , Hossam Tashkandi 1 , Anne B. Hofseth 1 , Corey Lane 1 , Edsel Pena 2 , Piaomu Liu 2 , Doug L. Pittman 1 , Prakash Nagarkatti 3 , Mitzi Nagarkatti 3 , Lorne J. Hofseth 1 and Alexander A. Chumanevich 1 1 Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, SC, USA 2 Department of Statistics, University of South Carolina, Columbia, SC, USA 3 School of Medicine, University of South Carolina, Columbia, SC, USA Correspondence to: Alexander A. Chumanevich, email: // Keywords : colitis, colon, inflammation, dextran sulfate sodium, CAM, FDA Received : November 11, 2016 Accepted : November 15, 2016 Published : December 10, 2016 Abstract Ulcerative colitis (UC) is a chronic lifelong inflammatory disorder of the colon, which, while untreated, has a relapsing and remitting course with increasing risk of progression toward colorectal cancer. Current medical treatment strategies of UC mostly focus on inhibition of the signs and symptoms of UC to induce remission and prevent relapse of disease activity, minimizing the impact on quality of life, but not affecting the cause of disease. To date, however, there is no single reliable treatment agent and/or strategy capable of effectively controlling colitis progression throughout the patient’s life without side effects, remission, or resistance. Taking into consideration an urgent need for the new colitis treatment strategies, targets and/or modulators of inflammation, we have tested current and prospective compounds for colitis treatment and directly compared their anti-colitis potency using a dextran sulfate sodium (DSS) mouse model of colitis. We have introduced a composite score – a multi-parameters comparison tool – to assess biological potency of different compounds.

Source: Oncotarget

DOI: 10.18632/oncotarget.13894